Reproductive hormonal treatments for mood disorders in women

Dialogues in Clinical Neuroscience

Volumn 4, Issue 2, 2002, Pages 211-223

  Schmidt, Peter J ^a   Rubinow, David R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Antidepressants; Depression; DHEA; Estrogen; Progesterone; Women

Indexed keywords

ANDROSTENEDIONE; ANTIDEPRESSANT AGENT; DANAZOL; DESOGESTREL; ESTRADIOL; ESTROGEN; GESTAGEN; GONADORELIN; GONADORELIN AGONIST; LEUPRORELIN; MIFEPRISTONE; ORAL CONTRACEPTIVE AGENT; PRASTERONE; PROGESTERONE; PROGESTERONE RECEPTOR MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE; TESTOSTERONE;

ARTICLE; BEHAVIOR; CLINICAL TRIAL; DRUG EFFECT; DRUG ISOLATION; DRUG SAFETY; ENDOMETRIUM CANCER; ESTROGEN THERAPY; HISTORY OF MEDICINE; HORMONAL THERAPY; HORMONE ACTION; HORMONE RELEASE; HUMAN; INVOLUTIONAL DEPRESSION; LONG TERM CARE; LUNG EMBOLISM; MOOD; MOOD DISORDER; PREMENSTRUAL SYNDROME; PUERPERAL DEPRESSION; REPRODUCTION; THROMBOSIS;

EID: 0037992788     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (189)

1. Barrus C. Gynecological disorders and their relation to insanity. Am J Psychiatry. 1895;51:475-491.
2. Sutherland H. Menstruation and insanity. In: Tuke DH, ed. A Dictionary of Psychological Medicine. Philadelphia, Pa: Blakistone P, Son & Co; 1892:801-803.
3. Esquirol E. Des maladies mentales considérées sous les rapports médicaux, hygiéniques et médico-légaux. Paris, France: JB Ballière; 1838.
4. English Lunacy Commissioners: Annual Reports to the Lord Chancellor, 1885-1901. London, UK: ELC; 1885.
5. Barnes F. On some psychological consequences of suppressed menstruation, 1896-1897. Br Gynaecol Soc. 1896;12:174-179.
6. Newbecker MM. The menstrual function in insane patients and the effects of ovariotomy. West Med Rev 1897;2:169-171.
7. Meyer A. On the diseases of women as a cause of insanity, in the light of observations in sixty-nine autopsies. Trans III Med Soc. 1895:299-311.
8. Carpenter EG. Pelvic disease as a factor of cause in insanity of females and surgery as a factor of cure. JAMA. 1900;35:545-551.
9. Savage GH. Some mental disorders associated with the menopause. Lancet. 1893;ii:1128.
10. Easterbrook CC. Organo-therapeutics in mental diseases. BMJ. 1900;2:813-823.
11. Brown-Séquard CE. The effects produced on man by subcutaneous injections of a liquid obtained from the testicles of animals. Lancet. 1889;2:105-107.
12. Herman JR. Rejuvenation: Brown-Séquard to Brinkley. Monkey glands to goat glands. N Y State J Med. 1982;82:1731-1739.
13. Aminoff MJ. Brown-Séquard: a Visionary of Science. New York, NY: Raven Press; 1993.
14. Schmidt P. Theorie und Praxis der Steinachschen Operation. Munich, Germany: Rikola Verlag; 1922.
15. Wilson JD. Charles-Edouard Brown-Séquard and the centennial of endocrinology. J Clin Endocrinol Metab. 1990;71:1403-1409.
16. Fosbery WHS. Severe climacteric flushings successfully treated by ovarian extract. BMJ. 1897;1:1039.
17. Fellner O. Experimentell erzeugte Wachstumsveräderungen am weiblichen Genitale der Kaninchen. Zentralbl Allg Pathol Anat. 1912;23:673-676.
18. Allen E, Doisy EA. An ovarian hormone: preliminary report on its location, extraction and partial purification, and action in test animals. JAMA. 1923;81:819-821.
19. Corner GW, Allen WM. Physiology of the corpus luteum. II. Production of a special uterine reaction (progestational proliferation) by extracts of the corpus luteum. Am J Physiol. 1929;88:326-346.
20. Colton FB. Steroids and "the pill": early steroid research at Searle. Steroids. 1992;57:624-630.
21. Goldzieher JW. The history of steroidal contraceptive development: the estrogens. Perspect Biol Med. 1993;36:363-368.
22. Perone N. The history of steroidal contraceptive development: the progestins. Perspect Biol Med. 1993;36:347-362.
23. Ettinger B. Overview of estrogen replacement therapy: a historical perspective. Proc Soc Exp Biol Med. 1998;217:2-5.
24. Werner AA, Johns GA, Hoctor EF, Ault CC, Kohler LW, Weis MW. Involutional melancholia: probable etiology and treatment. JAMA. 1934;103:13-16.
25. Sevringhaus EL. The use of folliculin in involutional states. Am J Obstet Gynecol. 1933;25:361-368.
26. Dalton K. Comparative trials of new oral progestogenic compounds in treatment of premenstrual syndrome. BMJ. 1959;1307-1309.
27. Israel S. Premenstrual tension. JAMA. 1938;110:1721-1723.
28. Schmidt HJ. The use of progesterone in the treatment of post-partum psychosis. JAMA. 1943;190-192.
29. Bower WH, Altschule MD. Use of progesterone in the treatment of postpartum psychosis. N Engl J Med. 1956;254:157-160.
30. Kane FJ Jr, Keeler MH. The use of enovid in postpartum mental disorders. South Med J. 1965;58:1089-1092.
31. Fraser IS. Forty years of combined oral contraception: the evolution of a revolution. Med J Aust. 2000;173:541-544.
32. Burkman RT, Collins JA, Shulman LP, Williams JK. Current perspectives on oral contraceptive use. Am J Obstet Gynecol. 2001;185:S4-S12.
33. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med. 1993;329:1141-1146.
34. Birge SJ, McEwen BS, Wise PM. Effects of estrogen deficiency on brain function. Implications for the treatment of postmenopausal women. Postgrad Med. 2001;Spec No:11-16.
35. Stein DG. Brain damage, sex hormones and recovery: a new role for progesterone and estrogen? Trends Neurosci. 2001;24:386-391.
36. Jensen JT, Speroff L. Health benefits of oral contraceptives. Obstet Gynecol Clin North Am. 2000;27:705-721.
37. King JA, Millar RP. Evolution of gonadotropin-releasing hormones. Trends Endocrinol Metab. 1992;3:339-346.
38. Matsuo H, Baba Y, Nair RMG, Arimura A, Schally AV. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun. 1971;43:1334-1339.
39. Vickery BH. Comparison of the potential for therapeutic utilities with gonadotropin-releaslng hormone agonists and antagonists. Endocr Rev 1986;7:115-124.
40. Casper RF. Clinical uses of gonadotropin-releasing hormone analogues. Can Med Assoc J. 1991;144:153-158.
41. Woolley CS, Schwartzkroin PA. Hormonal effects on the brain. Epilepsia. 1998;39:S2-S8.
42. Naftolin F, Leranth C, Horvath TL, Garcia-Segura LM. Potential neuronal mechanisms of estrogen actions in synaptogenesis and synaptic plasticity. Cell Mol Neurobiol. 1996;16:213-223.
43. McEwen BS, Woolley CS. Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain. Exp Gerontol. 1994;29:431-436.
44. McEwen BS, Alves SE, Bulloch K, Weiland NG. Ovarian steroids and the brain: implications for cognition and aging. Neurology. 1997;48(suppl 7):S8-S15.
45. Rachman IM, Unnerstall JR, Pfaff DW, Cohen RS. Estrogen alters behavior and forebrain c-fos expression in ovariectomized rats subjected to the forced swim test. Proc Natl Acad Sci U S A. 1998;95:13941-13946.
46. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry. 1998;44:839-850.
47. Pecins-Thompson M, Brown NA, Bethea CL. Regulation of serotonin reuptake transporter mRNA expression by ovarian steroids in rhesus macaques. Brain Res Mol Brain Res. 1998;53:120-129.
48. 1A receptors in hippocampal membranes from ovariectomized rats: functional and binding studies. Brain Res. 1990;518:287-291.
49. 1A receptor mRNA in female rat brain. Abstr Soc Neurosci. 1997;23:1501.
50. Kendall DA, Stancel GM, Enna SJ. Imipramine: effect of ovarian steroids on modifications in serotonin receptor binding. Science. 1981;211:1183-1185.
51. Menkes DB, Rasenick MM, Wheeler MA, Bitensky MW. Guanosine triphosphate activation of brain adenylate cyclase: enhancement by longterm antidepressant treatment. Science. 1983;129:65-67.
52. Perez J, Tinelli D, Brunello N, Racagni G. cAMP-dependent phosphorylation of soluble and crude microtubule fractions of rat cerebral cortex after prolonged desmethylimipramine treatment. Eur J Pharmacol. 1989;172:305-316.
53. Ozawa H, Rasenick MM. Chronic electroconvulsive treatment augments coupling of the GTP-binding protein Gs to the catalytic moiety of adenylyl cyclase in a manner similar to that seen with chronic antidepressant drugs. J Neurochem. 1991;56:330-338.
54. Nestler EJ, Terwilliger RZ, Duman RS. Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex. J Neurochem. 1989;53:1644-1647.
55. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54:597-606.
56. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element-binding protein (CREB) in rat hippocampus. J Neurosci. 1996;16:2365-2372.
57. Condorelli DF, Dell'Albani P, Mudo G, Timmusk T, Belluardo N. Expression of neurotrophins and their receptors in primary astroglial cultures: induction by cAMP-elevating agents. J Neurochem. 1994;63:509-516.
58. Singh M, Meyer EM, Simpkins JW. The effect of ovariectomy and estradiol replacement on brain-derived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of female Sprague-Dawley rats. Endocrinology. 1995;136:2320-2324.
59. Sohbrabji F, Miranda RC, Toran-Allerand CD. Estrogen differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. J Neurosci. 1994;14:459-471.
60. Panickar KS, Guan G, King MA, Rajakumar G, Simpkins JW. 17β-Estradiol attenuates CREB decline in the rat hippocampus following seizure. J Neurobiol. 1997;33:961-967.
61. Zhou Y, Watters JJ, Dorsa DM. Estrogen rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain. Endocrinology. 1996;137:2163-2166.
62. Sohrabji F, Greene LA, Miranda RC, Toran-Allerand CD. Reciprocal regulation of estrogen and NGF receptors by their ligands in PC12 cells. J Neurobiol. 1994;25:974-988.
63. Murphy DD, Cole NB, Segal M. Brain-derived neurotrophic factor mediates estradiol-induced dendritic spine formation in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95:11412-11417.
64. Epperson CE, Wisner KL, Yamamoto B. Gonadal steroids in the treatment of mood disorders. Psychosom Med. 1999;61:676-697.
65. Bancroft J. The premenstrual syndrome - a reappraisal of the concept and the evidence. Psychol Med. 1993;(suppl 24):1-47.
66. Rubinow DR. The premenstrual syndrome: new views. JAMA. 1992;268:1908-1912.
67. Wyatt K, Dimmock P, Jones P, Obhrai M, O'Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ. 2001;323:1-8.
68. Freeman E, Rickels K, Sondheimer SJ, Polansky M. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome. JAMA. 1990;264:349-353.
69. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA. 1995;274:51-57.
70. Schmidt PJ, Nieman LK, Grover GN, Muller KL, Merriam GR, Rubinow DR. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N Engl J Med. 1991;324:1174-1179.
71. Cullberg J. Mood changes and menstrual symptoms with different gestagen/estrogen combinations: a double-blind comparison with a placebo. Acta Psychiatr Scand. 1972;236(suppl):1-86.
72. Kutner SJ, Brown WL. Types of oral contraceptives, depression and premenstrual symptoms. J Nerv Ment Dis. 1972;155:153-162.
73. Graham CA, Sherwin BB. The relationship between retrospective premenstrual symptom reporting and present oral contraceptive use. J Psychosom Res. 1987;31:45-53.
74. Lewis A, Hoghughi M. An evaluation of depression as a side effect of oral contraceptives. Br J Psychiatry. 1969;115:697-701.
75. Woods NF, Most A, Dery GK. Prevalence of perimenstrual symptoms. Am J Public Health. 1982;72:1257-1264.
76. Marriott A, Faragher EB. An assessment of psychological state associated with the menstrual cycle in users of oral contraception. J Psychosom Res. 1986;30:41-47.
77. Slade P. Premenstrual emotional changes in normal women: fact or fiction? J Psychosom Res. 1984;28:1-7.
78. Sveindottir H, Backstrom T. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand. 2001;79:405-413.
79. Walker A, Bancroft J. Relationship between premenstrual symptoms and oral contraceptive use: a controlled study. Psychosom Med. 1990;52:86-96.
80. Bancroft J, Rennie D. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving, and other symptoms. J Psychosom Res. 1993;37:195-202.
81. Backstrom T, Hansson-Malmstrom Y, Lindhe BA, Cavalli-Bjorkman B, Nordenstrom S. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception. 1992;46:253-268.
82. Andersch B, Hahn L. Premenstrual complaints. II. Influence of oral contraceptives. Acta Obstet Gynecol Scand 1981;60:579-583.
83. Glick ID, Bennett SE. Psychiatric complications of progesterone and oral contraceptives. J Clin Psychopharmacol. 1981;1:350-367.
84. Herzberg BN, Johnson AL, Brown S. Depressive symptoms and oral contraceptives. BMJ. 1970;4:142-145.
85. Kutner SJ, Phillips NR, Hoag EJ. Oral contraceptives, personality, and changes in depression. Contraception. 1971;4:327-336.
86. Moos RH. Psychological aspects of oral contraceptives. Arch Gen Psychiatry. 1968;19:87-94.
87. Freeman EW, Sondheimer S, Weinbaum PJ, Rickels K. Evaluating premenstrual symptoms in medical practice. Obstet Gynecol. 1985;65:500-505.
88. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res. 1992;36:257-266.
89. Graham CA, Sherwin BB. The relationship between mood and sexuality in women using an oral contraceptive as a treatment for premenstrual symptoms. Psychoneuroendocrinology. 1993;18:273-281.
90. Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Women's Health Gend Based Med. 2001;10:561-569.
91. Watson NR, Savvas M, Studd JWW, Garnet T, Baber RJ. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet. 1989;2:730-732.
92. Watson NR, Studd JWW, Savvas M, Baber RJ. The long-term effects of estradiol implant therapy for the treatment of premenstrual syndrome. Gynecol Endocrinol. 1990;4:99-107.
93. Smith RNJ, Studd JWW, Zamblera D, Holland EFN. A randomised comparison over 8 months of 100 mg and 200 mg twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol. 1995;102:475-484.
94. Davis SR. Androgen treatment in women. Med J Aust. 1999;170:545-549.
95. Buckler HM, Misra R, Cantrill JA, Sheffield B, Anderson DC. The use of low dose (100 mg) testosterone implants in severe premenstrual syndrome (PMS). J Endocrinol. 1989;123:34.
96. Sheffield B, Buckler HM, Cantrill JA, Misra R, Anderson DC. Double-blind crossover trial of low dose testosterone implants in severe premenstrual syndrome (PMS). J Endocrinol. 1989;121:183.
97. Dhar V, Murphy BEP. Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology. 1990;15:489-493.
98. Halbreich U, Rojansky N, Palter S. Elimination of ovulation and menstrual cyclicity (with danazol) improves dysphoric premenstrual syndromes. Fertil Steril. 1991;56:1066-1069.
99. Hahn PM, Van Vugt DA, Reid RL. A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology. 1995;20:193-209.
100. Casson P, Hahn PM, VanVugt DA, Reid RL. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol. 1990;162:99-105.
101. Casper RF, Hearn MT. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am J Obstet Gynecol. 1990;162:105-109.
102. Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab. 1991;71:252A-252F.
103. Hussain SY, Massil JH, Matta WH, Shaw RW, O'Brien PMS. Buserelin in premenstrual syndrome. Gynecol Endocrinol. 1992;6:57-64.
104. Bancroft J, Boyle H, Warner P, Fraser HM. The use of an LHRH agonist, buserelin, in the long-term management of premenstrual syndromes. Clin Endocrinol. 1987;27:171-182.
105. Mezrow G, Shoupe D, Spicer D, Lobo R, Leung B, Pike M. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril. 1994;62:932-937.
106. Metcalf MG, Livesey JH, Braiden V. Assessment of the effect of ovarian suppressants on women with the premenstrual syndrome: iterative spectral analysis. J Psychosom Res. 1994;38:129-137.
107. Hammarback S, Ekholm UB, Backstrom T. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol (Copen). 1991;125:132-137.
108. West CP, Hillier H. Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome. Hum Reprod. 1994;9:1058-1063.
109. Freeman EW, Sondheimer SJ, Rickels K. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull. 1997;33:303-309.
110. Hammarback S, Backstrom T. Induced anovulation as a treatment of premenstrual tension syndrome: a double-blind cross-over study with GnRH agonist versus placebo. Acta Obstet Gynecol Scand. 1988;67:159-166.
111. Muse KN, Cetel NS, Futterman LA, Yen SSC. The premenstrual syndrome: effects of "medical ovariectomy." N Engl J Med. 1984;311:1345-1349.
112. Brown CS, Ling FW, Andersen RN, Farmer RG, Arheart KL. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol. 1994;84:779-786.
113. Helvacioglu A, Yeoman RR, Hazelton JM, Aksel S. Premenstrual syndrome and related hormonal changes: long-acting gonadotropin-releasing hormone agonist treatment. J Reprod Med. 1993;38:864-870.
114. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338:209-216.
115. Menkes DB, Taghavi E, Mason PA, Howard RC. Fluoxetine's spectrum of action in premenstrual syndrome. Int Clin Psychopharmacol. 1993;8:95-102.
116. Stone AB, Pearlstein TB, Brown WA. Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry. 1991;52:290-293.
117. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual syndrome. N Engl J Med. 1995;332:1529-1534.
118. Wood SH, Mortola JF, Chan YF, Moossazadeh F, Yen SSC. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet Gynecol. 1992;80:339-344.
119. Eriksson E, Lisjo P, Sundblad C, Andersson K, Andersch B, Modigh K. Effect of clomipramine on premenstrual syndrome. Acta Psychiatr Scand. 1990;81:87-88.
120. Sundblad S, Modigh K, Andersch B, Eriksson E. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand. 1992;85:39-47.
121. Su TP, Schmidt PJ, Danaceau MA, et al. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology. 1997;16:346-356.
122. Freeman EW, Rickels K, Sondheimer SJ, Denis A, Pfeifer S, Weil S. Nefazodone in the treatment of premenstrual syndrome: a preliminary study. J Clin Psychopharmacol. 1994;14:180-186.
123. Henshaw C, Foreman D, Belcher J, Cox J, O'Brien S. Can one induce premenstrual symptomatology in women with prior hysterectomy and bilateral oophorectomy? J Psychosom Obstet Gyn. 1996;17:21-28.
124. Halbreich U, Endicott J, Goldstein S, Nee J. Premenstrual changes and changes in gonadal hormones. Acta Psychiatr Scand. 1986;74:576-586.
125. Muse K. Gonadotropin-releasing hormone agonist-suppressed premenstrual syndrome (PMS): PMS symptom induction by estrogen, progestin, or both. Abstracts of the Annual Meeting for the Society of Gynecologic Investigation. San Diego, Calif. March 1989. 1989;118.
126. Wang M, Seippel L, Purdy RH, Bäckström T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5α-pregnane-3,20-dione and 3α-hydroxy-5α-pregnan-20-one. J Clin Endocrinol Metab. 1996;81:1076-1082.
127. Schmidt PJ, Rubinow DR. Mood and the perimenopause. Contemp Ob/Gyn. 1994;39:68-75.
128. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
129. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol. 2000;183:414-420.
130. Soares CD, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58:529-534.
131. Schmidt PJ, Murphy JH, Danaceau MA, Simpson-St Clair L. Basal plasma human levels in depressed perimeropausal women. Psychoneuroendocrinology. In press.
132. Coope J. Is oestrogen therapy effective in the treatment of menopausal depression? J R Coll Gen Pract. 1981;31:134-140.
133. Campbell S. Double-blind psychometric studies on the effects of natural estrogens on post-menopausal women. In: Campbell S, ed. The Management of the Menopause and Post Menopausal Years. Lancaster, UK: MTP Press; 1976:149-158.
134. George GCW, Utian WH, Beumont PJV, Beardwood CJ. Effect of exogenous oestrogens on minor psychiatric symptoms in postmenopausal women. S Afr Med J. 1973;47:2387-2388.
135. Montgomery JC, Brincat M, Tapp A, et al. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet. 1987;1:297-299.
136. Saletu B, Brandstatter N, Metka M, et al. Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression. Psychopharmacology. 1995;122:321-329.
137. Sherwin BB. Affective changes with estrogen and androgen replacement therapy in surgically menopausal women. J Affect Disord. 1988;14:177-187.
138. Klaiber EL, Broverman DM, Vogel W, Kobayashi Y. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry. 1979;36:550-554.
139. Ditkoff EC, Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol. 1991;78:991-995.
140. Zweifel JE, O'Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology. 1997;22:189-212.
141. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders: results from the PRIME-MD 1000 study. JAMA. 1995;274:1511-1517.
142. Appleby L, Montgomery J, Studd J. Oestrogens and affective disorders. In: Studd J, ed. Progress in Obstetrics and Gynaecology. Edinburgh, UK: Churchill Livingstone; 1981:289-302.
143. Bloch M, Daly RC, Rubinow DR. Endocrine factors in the etiology of postpartum depression. Compr Psychiatry. 2002. In press.
144. Bloch M, Schmidt PJ, Danaceau M, Murphy J, Nieman L, Rubinow DR. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry. 2000;157:824-930.
145. Dalton K. Progesterone prophylaxis used successfully in postnatal depression. Practitioner 1985;229:507-508.
146. Dalton K. Depression After Childbirth. Oxford, UK: Oxford University Press; 1980.
147. Lawrie TA, Hofmeyr GJ, DeJager M, Berk M, Paiker J, Viljoen E. A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. Br J Obstet Gynaecol. 1998;105:1082-1090.
148. Sichel DA, Cohen LS, Robertson LM, Ruttenberg A, Rosenbaum JF. Prophylactic estrogen in recurrent postpartum affective disorder. Biol Psychiatry. 1995;38:814-818.
149. Gregoire AJP, Kumar R, Everitt B, Henderson AF, Studd JWW. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 1996;347:930-933.
150. Ahokas A, Kaukoranta J, Wahlbeck K, Aito M. Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17β-estradiol: a preliminary study. J Clin Psychiatry. 2001;62:332-336.
151. Rubinow DR, Roy-Byrne PP. Premenstrual syndromes: overview from a methodologic perspective. Am J Psychiatry. 1984;141:163-172.
152. Rubinow DR, Schmidt PJ. Mood disorders and the menstrual cycle. J Reprod Med. 1987;32:389-394.
153. Meyers BS, Moline ML. The role of estrogen in late-life depression: opportunities and barriers to research. Psychopharmacol Bull. 1997;33:289-291.
154. Lebowitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment of depression in late life: consensus statement update. JAMA. 1997;278:1186-1190.
155. Plouffe L Jr, Simon JA. Androgen effects on the central nervous system in the postmenopausal woman. Semin Repro Endocrinol. 1998;16:135-143.
156. Schneider LS, Small GW, Hamilton SH, Bystritsky A, Nemeroff CB, Meyers BS. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Am J Geriatr Psychiatry. 1997;5:97-106.
157. Small GW, Schneider LS, Holman S, Brystritsky A, Meyers BS, Nemeroff CB. Estrogen plus fluoxetine for geriatric depression. Abstracts of the American Psychiatric Association 147th Annual Meeting. Los Angeles, Calif. May 1994. 1994;203.
158. Amsterdam J, Garcia-Espana F, Fawcett J, et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord. 1999;55:11-17.
159. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000;343:682-688.
160. Cohen AJ. Antidepressant-induced sexual dysfunction associated with low serum free testosterone. Psychiatry On-Line. 1999:1-5.
161. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984;59:551-555.
162. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab. 2000;85:2832-2838.
163. Snyder PJ. The role of androgens in women. J Clin Endocrinol Metab. 2001;86:1006-1007.
164. Wolkowitz OM, Reus VI, Roberts E, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry. 1997;41:311-318.
165. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of mid-life dysthymia. Biol Psychiatry. 1999;45:1533-1541.
166. Rabkin JG, Ferrando SJ, Wagner GJ, Rabkin R. DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters. Psychoneuroendocrinology. 2000;25:53-68.
167. Goggin K, Engelson ES, Rabkin JG, Kotler DP. The relationship of mood, endocrine, and sexual disorders in human immunodeficiency virus positive (HIV+) women: an exploratory study. Psychosom Med. 1998;60:11-16.
168. Grinspoon S, Corcoran C, Miller K, et al. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab. 1997;82:1332-1337.
169. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry. 2000;57:141-147.
170. Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab. 2000;85:60-65.
171. Daly RC, Schmidt PJ, Roca CA, Rubinow DR. Testosterone's effects not limited to mood. Letter to the editor. Arch Gen Psychiatry. 2000;57:155-156.
172. Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med. 1998;339:733-738.
173. Rubinow DR, Schmidt PJ, Zhang L, et al. Gonadal steroids and serotonin: development and treatment of mood disorders. Abstracts of the 7th World Congress in Biological Psychiatry. Nice, France. June 1997.
174. Bethea CL, Pecins-Thompson M, Schutzer WE, Gundlah C, Lu ZN. Ovarian steroids and serotonin neural function. Mol Neurobiol. 1998;18:87-123.
175. Bethea CL, Gundlah C, Mirkes SJ. Ovarian steroid action in the serotonin neural system of macaques. 2000 Neuronal and Cognitive Effects of Oestrogens, Chichester, UK: J. Wiley; 2000:112-130.
176. Roca CA, Schmidt PJ, Greenberg BD, Murphy DL, Rubinow DR. Serotonin and the efficacy of estrogen in perimenopausal depression. Abstracts of the 54th Annual Meeting of the Society of Biological Psychiatry. Washington DC. May 1999. 1999;45:765.
177. Krezel W, Dupont S, Krust A, Chambon P, Chapman PF. Increased anxiety and synaptic plasticity in estrogen receptor β-deficient mice. Proc Natl Acad Sci U S A. 2001;98:12278-12282.
178. Osterlund MK, Gustafsson JA, Keller E, Hurd YL. Estrogen receptor β (ERβ) messenger ribonucleic acid (mRNA) expression within the human forebrain: distinct distribution pattern to ERα mRNA. J Clin Endocrinol Metab. 2000;85:3840-3846.
179. Gundlah C, Kohama SG, Mirkes SJ, Garyfallou VT, Urbanski HF, Bethea CL. Distribution of estrogen receptor beta (ERβ) mRNA in hypothalamus, midbrain and temporal lobe of spayed macaque: continued expression with hormone replacement. Mol Brain Res. 2000;76:191-204.
180. Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab. 1999;84:3459-3462.
181. Katzenellenbogen BS, Choi I, Delage-Mourroux R, et al. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol. 2000;74:279-285.
182. Verbost PM, Herpen A, Veen C, Groothuis PG. Progesterone receptor modulators: cell and sub-cell specificity in agonism and antagonism. Abstracts of the 83rd Annual Meeting of the Endocrine Society. Denver, Co. June 2001. 2001;163.
183. Wiehle RD, Newby C, Kelleher PJ. The search for SPRMS (selective progesterone receptor modulators). Abstracts of the 83rd Annual Meeting of the Endocrine Society. Denver, Co. June 2001. 2001;163.
184. Gold PW, Chrousos GP. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Proc Assoc Am Physicians. 1998;111:22-34.
185. Michelson D, Stratakis C, Reynolds J, Galliven E, Chrousos G, Gold P. Bone mineral density in women with depression. N Engl J Med. 1996;335:664-666.
186. Knopp RH, Zhu X. Multiple beneficial effects of estrogen on lipoprotein metabolism. J Clin Endocrinol Metab. 1997;82:3952-3954.
187. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811.
188. Walker BR. Steroid metabolism in metabolic syndrome X. Best Prac Res Clin Endocr Metab. 2001;15:111-122.
189. Krishnan KRR, Hays JC, Blazer DG. MRI-defined vascular depression. Am J Psychiatry. 1997;154:497-501.